

## CURRICULUM VITAE

10 Mar 2011

**NAME:** Jeanette M. Podbielski, R.N., B.S.N.

**PRESENT TITLE:** Clinical Program Manager  
Center for Translational Injury Research

**ADDRESS:** University of Texas Health Science Center  
6410 Fannin St. Suite 1100  
Houston, TX, 77030  
Telephone: 713.500.6407  
Fax: 713.512.7135  
Email: [Jeanette.M.Podbielski@uth.tmc.edu](mailto:Jeanette.M.Podbielski@uth.tmc.edu)

### UNDERGRADUATE EDUCATION:

1980-1984 R.N., B.S., Nursing  
Grand View College, Des Moines, IA

### CLINICAL APPOINTMENTS:

1984 *Staff R.N.*  
St. Elizabeth Hospital, Beaumont, TX

1984-1986 *Staff R.N.*  
Golden Triangle Dialysis Center, Beaumont, TX

1986-1988 *Clinical Nurse*  
Baylor University Medical Center, Dallas, TX

1988-1990 *Director of Nursing*  
Southwest Houston Dialysis Center, Rosenberg, TX

1990-1991 *Renal Transplant Coordinator*  
University of Texas Health Science Center,  
Houston, TX

1991-1993 *Research Nurse*  
Department of Surgery, Transplantation  
University of Texas Health Science Center,  
Houston, TX

## **CLINICAL APPOINTMENTS (continued)**

1993-1997	<i>Senior Research Nurse</i> Department of Surgery, Transplantation University of Texas Health Science Center, Houston, TX
1997-2008	<i>Research Nursing Staff Supervisor</i> Department of Surgery, Transplantation University of Texas Health Science Center, Houston, TX
2008-2010	<i>Senior Research Nurse</i> Center for Translational Injury Research University of Texas Health Science Center, Houston, TX
2010-Present	<i>Clinical Program Manager</i> Center for Translational Injury Research University of Texas Health Science Center, Houston, TX

**LISCENSURE:** Active: State of Texas, Nursing

## **PROFESSIONAL ORGANIZATIONS AND COMMITTEES:**

2001	Member, Novartis Transplant Coordinator Advisory Committee
2004	Member, Wyeth Transplant Coordinator Advisory Committee
2003-Present	Member, Association of Clinical Research Nurses
2005-Present	Member, Research Nurse Advisory Committee University of Texas Health Science Center, Houston, TX
2011-Present	Member, Society of Clinical Research Associates

## **SERVICE TO THE COMMUNITY:**

2010	Member, Houston Livestock and Rodeo Committee Houston, TX
------	--



## PUBLICATIONS (continued)

9. Kahan BD, Knight R, Schoenberg L, **Podbielski J**, Kerman RH, Mahalati K, Yakupoglu Y, Aki FT, Katz S, Van Buren CT. Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience. *Transplant Proc.* 2003 May;35(3 Suppl):25S-34S. PMID: 12742465.
10. Podder H, **Podbielski J**, Hussein I, Katz S, Van Buren C, Kahan BD. Sirolimus improves the two-year outcome of renal allografts in African-American patients. *Transpl Int.* 2001 Jun;14(3):135-42. PMID: 11499902.
11. **Podbielski J**, Schoenberg L. Use of sirolimus in kidney transplantation. *Prog Transplant.* 2001 Mar;11(1):29-32. Review. PMID: 11357554.
12. Kahan BD, Napoli KL, **Podbielski J**, Hussein I, Katz SH, Van Buren CT. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes. *Transplant Proc.* 2001 Feb-Mar;33(1-2):1278. PMID: 11267290.
13. Podder H, **Podbielski J**, Hussein I, Katz SM, Van Buren CT, Kahan BD. Impact of sirolimus on renal transplant outcomes in African Americans. *Transplant Proc.* 2001 Feb-Mar;33(1-2):1226. PMID: 11267269.
14. Kahan BD, Napoli KL, Kelly PA, **Podbielski J**, Hussein I, Urbauer DL, Katz SH, Van Buren CT. Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. *Clin Transplant.* 2000 Apr;14(2):97-109. PMID: 10770413.
15. Kahan BD, **Podbielski J**, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. *Transplantation.* 1998 Oct 27;66(8):1040-6. PMID: 9808489.
16. Podder H, **Podbielski J**, Katz S, Van Buren C, Kahan BD. Use of sirolimus overcomes risk factor of African-American race. *Br J Surgery.* 1998 Jul; 85 Sup 2: 74.
17. Lewis R, **Podbielski J**, Munsell M, Katz S, Van Buren C, Kerman R, Kahan BD. Stability of renal allograft glomerular filtration rate in the cyclosporine era: 2-year follow-up. *Transplant Proc.* 1994 Oct;26(5):2619-21. PMID: 7940815.
18. Kerman RH, Kimball PM, Lindholm A, Van Buren CT, Katz SM, Lewis RM, McClain J, **Podbielski J**, Williams J, Kahan BD. Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival. *Transplantation.* 1993 Nov;56(5):1242-7. PMID: 8249130.
19. Kerman RH, Kimball PM, Lindholm A, Van Buren CT, Katz SM, Lewis RM, **Podbielski J**, Williams J, Kahan BD. Immune risk factors: impact on the incidence and diagnosis of rejection. *Transplant Proc.* 1993 Aug;25(4 Suppl 3):23-5 PMID: 8351709.

## **PUBLICATIONS (continued)**

20. Lewis RM, **Podbielski J**, Munsell M, Katz S, Van Buren C, Kerman R, Kahan B. Optimization and long-term evaluation of renal function in sandimmune-treated renal allograft recipients. *Transplant Proc.* 1993 Aug;25(4 Suppl 3):10-2. PMID: 8351704.
21. Lewis R, **Podbielski J**, Sprayberry S, Munsell M, Katz S, Rubin M, Kimball P, Van Buren CT, Kerman R, Kahan B. Stability of renal allograft glomerular filtration rate associated with long-term use of cyclosporine A. *Transplantation.* 1993 May;55(5):1014-7. PMID: 8497874.

## **PRESENTATIONS AND ABSTRACTS:**

1. Cotton BA, Reddy N, Hatch QM, **Podbielski J**, McNutt MK, Albarado R, Gill BS, Wade CE, Kozar RA, Holcomb JB. Damage control resuscitation reduced resuscitation volumes and improved survival in 390 damage control laparotomy patients. To be presented at the 131<sup>st</sup> Annual Scientific Meeting of the American Surgical Association, Boca Raton, FL, April 11-13, 2011.
2. Hatch QM, **Podbielski J**, Wade CE, Kozar RA, Holcomb JB, Cotton BA. The impact of closure at the first take-back: Complication burden and potential over-utilization of damage control laparotomy. 41<sup>st</sup> Annual Scientific Meeting of the Western Trauma Association, Big Sky, MT, February 27-March 5, 2011.
3. Hatch QM, **Podbielski J**, Wade CE, Kozar RA, Holcomb JB, Cotton BA. Current use of damage control laparotomy, closure rates and predictors of early fascial closure at first take back. 69<sup>th</sup> Annual Meeting of the American Association for the Surgery of Trauma, Boston, MA, September 22-25, 2010.
4. Cotton BA, Faz G, Hatch Q, **Podbielski J**, McCarthy J, Bai Y, Wade C, Kozar RA, Holcomb JB. Rapid thromboelastography (r-TEG) delivers real-time results that predict transfusion within one hour of admission. 69<sup>th</sup> Annual Meeting of the American Association for the Surgery of Trauma, Boston, MA, September 22-25, 2010.
5. **Podbielski J**, Holcomb J, Sauer RM. Translating Science from Bench to the Bedside. Center for Translational Injury Research. Innovations in the Management of Steam Cell Clinical Trials, University of Texas Health Science Center, Houston, TX, October 8, 2010.
6. Adams S, Cotton BA, Dipasupil E, **Podbielski J**, Zaharia A, McGuire MF, Jastrow K, Ware DN, Gill BS, Albarado R, Kozar RA, Gonzalez EA, Duke JR, Adams PR, Dyer CB, Holcomb JB. The unique pattern of complications in elderly trauma patients at a level 1 trauma center. American College of Surgeons Committee on Trauma, Region VI Meeting, Dallas, TX, November 6-7, 2009.

## PRESENTATIONS AND ABSTRACTS (continued)

7. Scerbo M, Lakhole A, Kent J, **Podbielski J**, Hinds D, Lopez S, Dipasupil E, David W, del Junco D, Duke J, Holcomb J. Reliable Reduction of Trauma Overtriage Based on Prehospital Data: A Conservation of Scarce Health Care Resources. Advanced Technology Applications for Combat Casualty Care (ATACCC), St. Pete Beach, FL, August 10-12, 2009.
8. **Podbielski J**. Target Blood Levels. RAD 2309 Study Coordinators, Novartis Pharmaceuticals Inc., March 23, 2007.
9. **Podbielski J**. Preparing for an FDA Audit. Association of Clinical Research Nurses, The University of Texas Health Science Center, Houston, TX, 2003.
10. **Podbielski J**. Managing the Complications of Sirolimus Therapy. Dallas Nephrologist Seminar, Dallas, TX, November 12, 2002.
11. **Podbielski J**. Quality of Life. Canadian Transplant Nursing Seminar, (via teleconference), October, 2002.
12. **Podbielski J**. Update on New Immunosuppressives in Transplantation. American Nephrology Nurses Association Chapter Meeting, Columbia, MO, August 2001.
13. **Podbielski J**. Sirolimus, a New Pathway of Immunosuppression. NATCO, The Organization of Transplant Professionals, 25<sup>th</sup> Anniversary Meeting, Orlando, FL, August 2000.
14. **Podbielski J**. Wyeth-Ayerst Pharmaceuticals Clinical Symposium. NATCO, The Organization of Transplant Professionals, 25<sup>th</sup> Anniversary Meeting, Orlando, FL, August 2000.
15. **Podbielski J**. Sirolimus Clinical Trials. Wyeth Ayerst Preceptorship Programs, Houston, TX, 1998.
16. Lewis R, **Podbielski J**. Evolution of Native Kidney and Renal Transplant Function in Patients Receiving Long-Term Cyclosporine Therapy. Issues in Transplantation, Houston, TX, April 1992.
17. **Podbielski J**, McClain J. New Immunological Drug Therapy: Brequinar and Rapamycin. Organ Transplantation in the 21<sup>st</sup> Century, Houston, TX, April 1992.